Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formulary Balancing Act: Medicare Rules Weigh Access Versus Cost Control

Executive Summary

The Medicare prescription drug benefit implementing regulations would require formularies to contain at least two drugs in every therapeutic class

You may also be interested in...



USP Working Toward Medicare Formulary PBMs Can Use, McClellan Says

U.S. Pharmacopeia will make sure its model Medicare formulary guidelines "work" for prescription drug plan sponsors as it constructs the final version, Centers for Medicare & Medicaid Services Administrator Mark McClellan says

USP Working Toward Medicare Formulary PBMs Can Use, McClellan Says

U.S. Pharmacopeia will make sure its model Medicare formulary guidelines "work" for prescription drug plan sponsors as it constructs the final version, Centers for Medicare & Medicaid Services Administrator Mark McClellan says

USP Model Is “Starting Point”; CMS Formulary Standards Will Be True Test

U.S. Pharmacopeia's model drug classification system is only a "starting point" in developing a Medicare formulary that will pass muster with the Centers for Medicare & Medicaid Services

Related Content

Topics

UsernamePublicRestriction

Register

PS044425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel